Open AccessPoly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
Author(s) -
Jingsong Zhang
Publication year - 2014
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/1008-682x.123684
Subject(s) - parp inhibitor , prostate cancer , poly adp ribose polymerase , parp1 , pten , cancer research , polymerase , androgen receptor , medicine , prostate , cancer , biology , gene , genetics , pi3k/akt/mtor pathway , apoptosis
Recent phase I studies have reported single-agent activities of poly (ADP-ribose) polymerase (PARP) inhibitor in sporadic and in BRCA-mutant prostate cancers. Two of the most common genetic alterations in prostate cancer, ETS gene rearrangement and loss of PTEN, have been linked to increased sensitivity to PARP inhibitor in preclinical models. Emerging evidence also suggests that PARP1 plays an important role in mediating the transcriptional activities of androgen receptor (AR) and ETS gene rearrangement. In this article, the preclinical work and early-phase clinical trials in developing PARP inhibitor-based therapy as a new treatment paradigm for metastatic prostate cancer are reviewed.